Pfizer Inc. (PFE)
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.
Pfizer Stock: The Reversal Should Keep Going
Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement. The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical information on social media.
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims
The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart.
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period.
Is It Too Late to Buy Pfizer Stock?
Pfizer's recent financial performance has some investors questioning its future. The critics aren't entirely wrong -- the pharmaceutical giant does face challenges.
